產(chǎn)品名稱 |
RL |
商品貨號 |
B165606 |
Organism |
Homo sapiens, human |
Tissue |
ascites |
Cell Type |
B lymphoblast |
Product Format |
frozen |
Morphology |
lymphoblast |
Culture Properties |
suspension |
Biosafety Level |
1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
Disease |
non-Hodgkin's lymphoma |
Age |
52 years |
Gender |
male |
Ethnicity |
Caucasian |
Karyotype |
the cells possess a 14:18 translocation |
Derivation |
RL is a human non-Hodgkin's lymphoma B cell line originated in 1983 by Walter J. Urba and Dan L. Longo. |
Clinical Data |
52 years Caucasian male |
Antigen Expression |
CD19 +; CD20 +; CD21 +; CD22 +; Hle-1 +; HLA DQ +; HLA DR +; CD25 -; T cell receptor (TCR) - |
Genes Expressed |
immunoglobulin; surface IgM and IgD; secreted IgM (low levels) |
Cellular Products |
immunoglobulin; surface IgM and IgD; secreted IgM (low levels) |
Comments |
Exposure of RL cells to protein kinase C activating phorbol esters such as PMA and PdBu induced profound growth inhibition.
RL cells have been reported to be Epstein-Barr virus genome negative.
|
Complete Growth Medium |
The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, ATCC 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum (ATCC 30-2020) to a final concentration of 10%.
|
Subculturing |
Cultures can be maintained by addition or replacement of medium. Establish new cultures at 2 x 105 viable cells/mL and maintain between 1 x 105 and 1 x 106.
Medium Renewal: 2 to 3 times a week. |
Cryopreservation |
Culture medium, 95%; DMSO, 5% |
STR Profile |
Amelogenin: X,Y CSF1PO: 10 D13S317: 8,11 D16S539: 12 D5S818: 12 D7S820: 10,13 THO1: 9,10 TPOX: 9,11 vWA: 19,20 |
Isotype |
IgM; lambda light chain |
Name of Depositor |
M Beckwith |
Deposited As |
Homo sapiens |
References |
Beckwith M, et al. Phorbol ester-induced, cell-cycle-specific, growth inhibition of human B-lymphoma cell lines. J. Natl. Cancer Inst. 82: 501-509, 1990. PubMed: 2313723
|